DEALS

Zhong Lun Advises on LianBio’s IPO on Nasdaq

Release time：2021-11-02 Voice Announcements

On November 1, 2021, LianBio (Nasdaq: LIAN) announced its initial public offering and listing of American depositary shares on the Nasdaq Global Market. The total offering size will be US$ 325 million prior to the exercise of the over-allotment option. Goldman Sachs, Jefferies and BofA Securities acted as the joint book-running managers for this offering.

LianBio is a biotechnology company dedicated to bringing innovative therapeutic solutions to patients in Greater China and other major Asian markets. It was founded by Perceptive Advisors, a leading life sciences-focused investment firm. In accordance with relevant listing rules, LianBio filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for this offering.

Zhong Lun Law Firm acted as the PRC legal advisor for the issuer in this offering. The legal team from Zhong Lun was led by Anthony Zhao and William Jia and included Roy Zheng, Lindsay Zhang, Ruby Zheng, etc.

Previous：Zhong Lun Represents Client in UK Anti-Dumping Transition Review on Certain PSC Wires and Strands and Secures a Complete Victory Next：Zhong Lun Helps Accomplish Restructuring of Guangzhou Huakang as its Administrator

Print articles from Zhong Lun

Insights >

Publiciations >

Monthly Highlights >

Articles

Deals

Zhong Lun Advises Trinity CineAsia on the Acquisition of Hit Animation Ne Zha 2 across 37 Countries and Regions

Zhong Lun Assists Hisky Medical with Series D Financing

Events

Awards

Zhong Lun Advises on LianBio’s IPO on Nasdaq